Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same quarter last year, the firm posted ($1.32) earnings per share.

Analyst Vikram Purohit of Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), retaining the price target of $125.00. Vikram Purohit’s rating is based on ...

NASDAQ AXSM opened at $106.46 on Wednesday. Axsome Therapeutics has a one year low of $64.11 and a one year high of $111.51. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 ...

H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $190 from $180 and keeps a Buy rating on the shares. The firm says AXS-07 approval in acute treatment of migraine ...

Ratings for Axsome Therapeutics AXSM were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ...

NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

Jan 30 (Reuters) - The U.S. Food and Drug Administration has approved Axsome Therapeutics' (AXSM.O), opens new tab migraine treatment, the company said on Thursday. The oral drug, branded Symbravo ...